Trusted results from the scientific community
Please click on a tab to view each report.
Efficacy of the Violett L Standalone Indoor Air Purifier Against Aerosolized MS2 Bacteriophage
Purpose
This study was done to test a prototype version of the Violett L for its efficacy at reducing a single microorganism, the bacteriophage MS2, from indoor room air.
background
This in-vitro study characterized the efficacy of Violett L, indoor air purifier, to reduce respirable bioaerosol levels for a single viral bioaerosol from the air in a 16m3 stainless steel bioaerosol test chamber. The species selected for this study was the virus MS2, a bacteriophage, which is a recognized surrogate for more dangerous pathogenic organisms. MS2 is a non-enveloped ssRNA virus that is a common surrogate for influenza viruses and is a tentative surrogate for SARS-CoV-2.
MEthods
MS2 bacteriophage was aerosolized into a sealed 16m3 environmental bioaerosol chamber, containing the Violett L, using a Collison 24-Jet Nebulizer. The MS2 bioaerosols had a mass median aerodynamic diameter (MMAD) averaging at 0.7µm (700nm). Bioaerosol samples were taken, with impingers, at multiple time points throughout each trial, in order to quantify the reduction rate capability of the air purification device. The impinger samples were serially diluted, plated, incubated, and enumerated in triplicate to yield viable bioaerosol concentration for each sampling point. Chamber control trial data, or natural decay rate, was subtracted from the device trial data to yield the net log reduction for each of the bioaerosol challenges.
results
The device achieved an average log reduction of 6.45 +/- 0.28 within 30 minutes. This equates to a netlog reduction of 6.21 +/- 0.28 (> 99.9999%) when accounting for control losses. These results show that the Violett L device is extremely effective at the rapid removal of viral bioaerosols from room air, achieving a 4 net log (99.99%) reduction within eighteen (18) minutes.
conclusions
In conclusion, the Violett L device achieved >4 net log reduction of MS2 bacteriophage bioaerosols within a short period of time by achieving a 6.21 (99.9999%) net log reduction within thirty (30) minutes. It is anticipated that such a reduction should reduce the likelihood of individuals being exposed to and contracting airborne infectious diseases in any enclosed environment, medical or otherwise.
Efficacy of the Violett M Standalone Indoor Air Purifier Against Aerosolized MS2 Bacteriophage
Purpose
This study was done to test a prototype version of the Violett M for its efficacy at reducing a single microorganism, the bacteriophage MS2, from indoor room air.
background
This in-vitro study characterized the efficacy of Violett M, indoor air purifier, to reduce respirable bioaerosol levels for a single viral bioaerosol from the air in a 16m3 stainless steel bioaerosol test chamber. The species selected for this study was the virus MS2, a bacteriophage, which is a recognized surrogate for more dangerous pathogenic organisms. MS2 is a non-enveloped ssRNA virus that is a common surrogate for influenza viruses and is a tentative surrogate for SARS-CoV-2.
MEthods
MS2 bacteriophage was aerosolized into a sealed 16m3 environmental bioaerosol chamber, containing the Violett M, using a Collison 24-Jet Nebulizer. The MS2 bioaerosols had a mass median aerodynamic diameter (MMAD) averaging at 0.7µm (700nm). Bioaerosol samples were taken, with impingers, at multiple time points throughout each trial, to quantify the reduction rate capability of the air purification device over time. The impinger samples were serially diluted, plated, incubated, and enumerated in triplicate to yield viable bioaerosol concentrations for each of the sampling timepoints. Chamber control trial data, or the natural loss rate, was subtracted from the device trial data to yield the net log reduction for each of the bioaerosol challenges.
results
The device achieved an average log reduction of -6.77 +/- 0.09 in 60 minutes. This equates to a net log reduction of 6.42 +/- 0.09 (> 99.999961%) when accounting for control losses. These results show that the Violett M device is extremely effective at the rapid removal of viral bioaerosols from room air, achieving a 4-net log (99.99%) reduction within thirty-five (35) minutes.
conclusions
In conclusion, the Violett M device achieved >4 net log reduction of MS2 bacteriophage bioaerosols within about thirty-five minutes and a 6.42 net log (>99.9999%) reduction within sixty (60) minutes of operation. It is anticipated that such a reduction should reduce the likelihood of individuals being exposed to and contracting airborne infectious diseases in any enclosed environment, medical or otherwise.